Navigation Links
UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease
Date:10/18/2010

ATLANTA, Oct. 18 /PRNewswire/ -- Findings from the PRECiSE 3 (P3) open label extension study for Cimzia® (certolizumab pegol; CZP), demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20.  Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

Results of the P3 open-label extension study showed that continuous therapy with Cimzia provided long-term remission for more than 4.5 years in patients who initially responded to Cimzia in the six-month PRECiSE 2 study (P2).  In the PRECISE 2 double blind, placebo controlled clinical trial, 48% of patients achieved remission at six months.  Sustained long-term remission was observed among patients who had previous anti-TNF exposure (77% remission), as well as anti-TNF naive patients (73% remission).  

Similarly, results of the P4 open-label extension study showed long-term remission rates among patients treated with Cimzia (naive – 63%; non-naive – 50%).  For some patients, disease remission was achieved in as early as 4 weeks (38% of patient population).  Additionally, the data demonstrates that patients who are losing response to Cimzia or experience an interruption in therapy can be recaptured with one additional dose of Cimzia.  The data suggests re-induction therapy may have long-term benefits in helping patients who experienced drug interruption or loss of initial response achieve response and maintain remission.

"Collectively, these Cimzia data findings are important for patients living with moderate to severe Crohn's disease and the gastroenterologists treating them, as long-term remission is the ultimate goal of treatment," said Cem Kayhan, MD, Medical Director at UCB.  "It
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015  Abbott (NYSE: ABT ) announced ... multi-center, randomized trial comparing the safety and effectiveness of ... ® , Abbott,s market-leading, permanent drug eluting stent. The ... Japan and enrolled 400 people with coronary ... The results will be featured at a late-breaking session ...
(Date:9/1/2015)... Quebec , Sept. 1, 2015  Valeant ... TSX: VRX) today announced that its affiliate has ... which Valeant was granted an exclusive license to ... is an IL-17 receptor monoclonal antibody in development ... arthritis. Under the agreement, Valeant will hold the ...
(Date:8/31/2015)... TWINSBURG, Ohio , Aug. 31, 2015 /PRNewswire/ ... and applications, has acquired MACTek Corporation, a leading ... part of Pepperl+Fuchs, strategy to further extend its ... the WirelessHART market.    "We are ... to our existing portfolio," said Jim Bolin ...
Breaking Medicine Technology:Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
(Date:9/1/2015)... ... September 01, 2015 , ... ... Archiver for Alfresco, a next-generation customer communications archiving solution integrated with Alfresco‘s ... technology from Crawford and helps organizations save millions of dollars in printing ...
(Date:9/1/2015)... New York (PRWEB) , ... September 01, 2015 , ... ... one of the Super Lawyers 2015 for his third consecutive year in a row. ... achievements and accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo ...
(Date:9/1/2015)... ... 01, 2015 , ... September is Baby Safety Month, and Lightning Labels ... to keep little ones' safety top of mind at all times. , Sponsored by ... According to the JPMA's Baby Safety Zone website, this year's theme is A Room ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... the release of ten hours of new premium on-demand video Evidence Based ... , Athletic Trainers certified before 2014 must complete 50 CEUs before December 31, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly ... Power and Influence by Modern Luxury’s The Atlantan Magazine. , This award ... as Kathy King. Her idea and vision to bring to Atlanta a true ...
Breaking Medicine News(10 mins):Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... has been an evident reduction in the breast cancer cases ... this, and one conceivable reason has particularly caught their attention. ... 2002. Whether mere reduction in HRT has brought out such ... has been an almost 7 percent reduction in the number ...
... people with history of unprotected sex to have an ... transmission.// The announcement being the first case of such ... Thursday uncovered two clusters of HIV infections, HIV-1 subtype ... government scientists. They said that both the clusters found ...
... it as a 'citizens raid', Bhopal gas tragedy survivors' ... sub-standard and expired drugs from two medical stores of ... ,"A joint team of four organisations, working for ... recovered many medicines that had crossed their expiry date," ...
... University of Pennsylvania Health System are starting a trial ... its electrical pulses// essentially short-circuit, referred to as atrial ... into with current therapies to cope with electrical rhythmic ... procedures, is that up until now, they’ve had to ...
... while ‘over the limit,’ but subsequently found to be below ... range of drugs, reveals research in Injury Prevention. ... testing in all drivers who are suspected of being over ... findings on 2000 blood and urine specimens taken from drivers ...
... The route to a man’s heart is through his stomach, they ... the kitchen? Food for thought, of course! Meanwhile, what could be ... the attention of the lady of the house, says a new ... embarked on a study of almost 200 British men and women, ...
Cached Medicine News:Health News:New Tool Being Tested to Halt Recurrence of Atrial Fibrillation 2Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:How a Woman Holds Fort in Her Little Kingdom – The Kitche 2
Inquire...
Inquire...
... optical performance, the SZX7 is designed for ... every task, from routine preparations to advanced ... best zoom ratios in its class as ... and accurate reproduction of the original specimen ...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
Medicine Products: